摘要

PURPOSE:The application of the tumor-specific genomic fusion sequence as noninvasive biomarker for therapy monitoring in Ewing sarcoma (EwS) has been evaluated.
EXPERIMENTAL DESIGN:EwS xenograft mouse models were used to explore detectability in small plasma volumes and correlation of genomic EWSR1-FLI1 copy numbers with tumor burden. Furthermore, 234 blood samples from 20 EwS patients were analyzed before and during multimodal treatment. EWSR1 fusion sequence levels in patients' plasma were quantified using droplet digital PCR and compared with tumor volumes calculated from MRI or CT imaging studies.
RESULTS:Kinetics of EWSR1 fusion sequence copy numbers in the plasma are correlated with changes of the tumor volume in patients with localized and metastatic disease. The majority of patients showed a fast reduction of cell-free tumor DNA (ctDNA) during initial chemotherapy. Recurrence of increasing ctDNA levels signalized relapse development.
CONCLUSIONS:Genomic fusion sequences represent promising noninvasive biomarkers for improved therapy monitoring in EwS. Until now, response assessment is largely based on MRI and CT imaging, implying restrictions on closely repeated performance and limitations on the differentiation between vital tumor and reactive stromal tissue. Particularly in patients with prognostic unfavorable disseminated disease, ctDNA is a valuable addition for the assessment of therapy response. Clin Cancer Res; 22(17); 4356-65. ©2016 AACR.

译文

目的: 已经评估了肿瘤特异性基因组融合序列作为无创生物标志物在尤因肉瘤 (EwS) 治疗监测中的应用。
实验设计: 使用 EwS 异种移植小鼠模型来探索小血浆体积的可检测性以及基因组 EWSR1-FLI1 拷贝数与肿瘤负荷的相关性。此外,在多模式治疗之前和期间分析了来自 20 名 EwS 患者的 234 份血样。使用微滴数字 PCR 定量患者血浆中的 EWSR1 融合序列水平,并与从 MRI 或 CT 成像研究中计算的肿瘤体积进行比较。
结果: 血浆中 EWSR1 融合序列拷贝数的动力学与局部和转移性疾病患者的肿瘤体积变化相关。大多数患者在初始化疗期间表现出无细胞肿瘤 DNA (ctDNA) 的快速减少。CtDNA 水平增加的复发预示着复发发展。
结论: 基因组融合序列代表了改善 EwS 治疗监测的有希望的无创生物标志物。到目前为止,反应评估主要基于 MRI 和 CT 成像,这意味着对密切重复表现的限制和对重要肿瘤和反应性基质组织之间区别的限制。特别是在预后不利的播散性疾病患者中,ctDNA 是评估治疗反应的有价值的补充。Clin Cancer Res; 22 (17); 4356-65。©2016 AACR。

tumor marker

消化 肿瘤筛查 临床研究术语
概述  :  

肿瘤标志物,是指特征性存在于恶性肿瘤细胞,或由恶性肿瘤细胞异常产生的物质,或是宿主对肿瘤的刺激反应而产生的物质,并能反映肿瘤发生、发展,监测肿瘤对治疗反应的一类物质。肿瘤标志物存在于肿瘤患者的组织、体液和排泄物中,能够用免疫学、生物学及化学的方法检测到。 常见肿瘤标志物糖类抗原125(CA125):正常参考值:≤35U/ml。CA125存在于上皮卵巢癌组织和患者血清中,是一个被研究的最多的卵巢癌肿瘤标志物,在早期筛查、诊断、治疗及预后的应用研究均有重要意义。CA125对卵巢上皮癌的

tumor 英 /'tju:mə(r)/  美 /'tjʊmɚ/

释义   n. 肿瘤;肿块;赘生物

例句   He took a deep breath. "But there is no sign of tumor ---nothing at all---in your breast tissue. 他深深地呼了口气, 接著说:"但你的乳腺组织里没有肿瘤的迹象——什么都没有。

 

marker 英 /ˈmɑːkə(r)/  美 /ˈmɑːrkər/

释义   n. (表示方位的)标记;性质或状况的)标志

例句   Obesity does not cause the defects but is a marker for other factors that do. 

肥胖并不是导致缺陷的原因,但它是导致缺陷的其他因素的标志。


请扫描右侧二维码,免费查看词汇专业知识背景